Neko Health has raised $700 million in a Series C round at a $7 billion valuation, according to the Financial Times. The jump from a $1.7 billion valuation just over a year ago marks roughly a fourfold increase—a steep climb for any healthcare startup, let alone one still building its US presence.

The company, founded in 2018 by Spotify co-founder Daniel Ek and led by CEO Hjalmar Nilsonne, operates body-scanning clinics that combine AI-powered image analysis with blood tests to screen for skin cancer, heart disease, and diabetes risk factors. Eight clinics currently run across the UK and Sweden; a New York location is planned for 2025. Scans run £299 in the UK and 2,750 Swedish kronor in Sweden. More than 350,000 people have joined waitlists or registered, with 100,000 scans completed.

What stands out about the Series C investor roster is its composition. New backers include will.i.am, Maria Sharapova, Mark Zuckerberg and Priscilla Chan, and Thierry Henry—alongside existing investors Reddit co-founder Alexis Ohanian and actor Zoë Saldaña. The presence of celebrity and tech-adjacent capital over traditional healthcare investors signals a shift in how consumer-health startups are building distribution: through cultural affinity and brand trust rather than clinical networks alone.

The US market will test whether Neko's model works at scale outside its home region. The UK and Sweden have regulatory environments that differ substantially from the US, where FDA device classification, state-level medical licensing, and the absence of insurance coverage for elective preventive scans shape economics quite differently. The company has not disclosed which regulatory pathway its US devices will follow or how US pricing will work.

Neko sits within a broader category—consumer-facing preventive diagnostics powered by machine learning—that has attracted venture capital in waves over the past decade. Other players like Prenuvo offer full-body MRI scans. Neko's competitive edge lies in proprietary scanning hardware rather than adapted existing equipment; that distinction affects both regulatory classification and how insurers and clinicians will eventually interpret and act on the results.

The pattern worth watching here is familiar from past cycles. Celebrity-backed health-tech rounds—in wearables, at-home genetic testing, and other spaces—have sometimes outpaced the clinical validation and insurance reimbursement clarity needed to sustain operations at scale. None of the available reporting indicates that dynamic is at play with Neko, but with limited disclosed revenue metrics and a valuation built substantially on this single Series round, scrutiny independent of investor prestige seems warranted. As Neko moves into a regulatory and reimbursement landscape far more fragmented than what it has navigated in Sweden or the UK, how the company clears those hurdles will matter more than the headline valuation.

What Neko is betting on is that AI-assisted screening at accessible price points can shift preventive health from an occasional clinical event into routine maintenance. If the detection accuracy holds up under US regulatory review, that proposition could widen access to early screening for populations who do not regularly see specialists. Whether the New York clinic validates that bet—or exposes the limits of exporting a Nordic-and-UK model to US healthcare economics—will be a closely watched test in consumer health tech this year.